Neurogranin (Ng) Synaptic Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurogranin (Ng) is a postsynaptic neuronal protein that serves as a sensitive biomarker for synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders[1].
Neurogranin is a 78-amino acid protein encoded by the RC3 (RC3/Ng) gene, also known as neurogranin or RC3. It is highly enriched in dendritic spines of excitatory neurons in the hippocampus and cerebral cortex[2]. As a biomarker, neurogranin reflects the loss of synaptic integrity, which is a hallmark of cognitive decline in neurodegenerative diseases.
| Property | Value |
|---|---|
| Gene | RC3 (Receptor Capping 3) |
| Protein Name | Neurogranin |
| UniProt ID | P84902 |
| Molecular Weight | ~8.7 kDa |
| Brain Expression | Hippocampus, Cortex |
| Cellular Localization | Postsynaptic dendritic spines |
Neurogranin plays several critical roles in synaptic plasticity[3]:
Cerebrospinal fluid (CSF) neurogranin levels are elevated in Alzheimer's disease and correlate with[4][5]:
| Condition | CSF Neurogranin Level | Clinical Interpretation |
|---|---|---|
| Alzheimer's Disease | ↑ Elevated | Synaptic loss, disease progression |
| MCI due to AD | ↑ Moderately elevated | Early synaptic dysfunction |
| Frontotemporal Dementia | Normal to slightly elevated | Less synaptic involvement |
| Parkinson's Disease | Normal | Minimal cortical synaptic loss |
| Healthy Controls | Low baseline | Normal synaptic integrity |
In neurodegenerative diseases, neurogranin is released into CSF due to[6]:
Neurogranin is increasingly used as a biomarker in AD clinical trials[7]:
| Method | Sample | Advantages |
|---|---|---|
| ELISA | CSF | High sensitivity, widely available |
| Simoa | CSF/Plasma | Ultra-sensitive, can detect in blood |
| Western Blot | CSF | Confirms protein identity |
| Mass Spectrometry | CSF | High specificity, multiplex capable |
Large-scale validation studies have confirmed neurogranin's utility as a biomarker for synaptic dysfunction in Alzheimer's disease. Multi-center studies have demonstrated the robustness of CSF neurogranin measurements across different assay platforms and laboratories. These studies have established standardized protocols for clinical implementation.
Neurogranin complements other synaptic biomarkers including SNAP-25, synaptotagmin, and synaptophysin. While each marker provides unique insights into different aspects of synaptic pathology, neurogranin has shown particular sensitivity to Alzheimer's disease-related synaptic changes. The combination of multiple synaptic biomarkers may provide more comprehensive assessment of neurodegeneration.
The study of Neurogranin (Ng) Synaptic Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Portelius E, Zetterberg H, Andreasson U, et al. An Alzheimer's disease-related biomarker network based on CSF proteins and ADNI data. J Alzheimers Dis. 2015;47(1):105-114. DOI:10.3233/JAD-150149 ↩︎
Díaz-Moreno M, Ar镇的-Carbó M, Ortego M, et al. Neurogranin is expressed in the brain and spinal cord but not in the peripheral nervous system. Neurosci Lett. 2010;472(3):171-174. DOI:10.1016/j.neulet.2010.02.011 ↩︎
Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007;8(2):101-113. DOI:10.1038/nrn2055 ↩︎
Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2015;11(10):1180-1190. DOI:10.1016/j.jalz.2014.10.009 ↩︎
Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829-835. DOI:10.1212/WNL.0000000000002423 ↩︎
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144. DOI:10.1038/nrneurol.2010.4 ↩︎
Mattsson N, Schindler M, Zetterberg H, et al. Longitudinal CSF neurogranin in Alzheimer's disease: a biomarker for synaptic pathology. Ann Clin Transl Neurol. 2018;5(5):630-639. DOI:10.1002/acn3.556 ↩︎